Minerva Neurosciences (NASDAQ:NERV) Releases Quarterly Earnings Results, Beats Expectations By $0.49 EPS

Minerva Neurosciences (NASDAQ:NERV) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.49, Zacks reports.

Minerva Neurosciences Stock Performance

NASDAQ NERV opened at $1.79 on Tuesday. Minerva Neurosciences has a one year low of $1.77 and a one year high of $7.53. The company has a 50-day simple moving average of $2.18 and a 200-day simple moving average of $2.40. The firm has a market capitalization of $12.52 million, a PE ratio of -4.07 and a beta of 0.12.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on NERV shares. HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a research note on Wednesday, November 6th. StockNews.com began coverage on Minerva Neurosciences in a report on Saturday. They issued a “sell” rating for the company.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.